Cochrane · systematic review · CD012014
Oral water soluble contrast for malignant bowel obstruction
Syrmis, W, Richard, R, Jenkins-Marsh, S, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
5
Included studies
NR
No studies 5 · 71.4%Ungraded 0 · 0%Very low 2 · 28.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: Adults 18 yrs and over with malignant bowel obstruction (MBO) as defined by the International Conference on MBO, with no indication for other treatments e.g. surgery, endoscopy, etc
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
The ability of OWSC, when seen to reach the colon on | no estimate extracted | NR | No studies |
The rate of resolution of MBO with medical management only in patients receiving OWSC compared with those not receiving it (therapeutic). | no estimate extracted | NR | No studies |
Gastrointestinal adverse effects (increased abdominal pain, nausea, vomiting). | no estimate extracted | 1 study · 9 participants | Very low Downgraded: risk of bias, imprecision |
Extra‐abdominal complications (aspiration pneumonia, hypersensitivity reactions). | no estimate extracted | 1 study · 9 participants | Very low Downgraded: risk of bias, imprecision |
Length of hospital stay. | no estimate extracted | NR | No studies |
Time from administration of OWSC to resolution of MBO. | no estimate extracted | NR | No studies |
Survival time from onset of inoperable MBO until death. | no estimate extracted | NR | No studies |